In recent years, targeted protein degradation (TPD) technology has emerged as a groundbreaking approach in drug discovery. By harnessing the ubiquitin-proteasome system or lysosomal pathways, protein degraders (e.g., PROTACs, molecular glues, and LYTACs) selectively induce the degradation of disease-related proteins, offering novel solutions for traditionally "undruggable" targets. 

Although TPD technology has demonstrated broad application prospects in multiple fields, several challenges remain to be overcome. These include improving degradation efficiency and specificity, reducing off-target effects, and ensuring in vivo safety. Additionally, the clinical translation of TPD faces numerous hurdles, such as drug stability, pharmacokinetic properties, and potential long-term toxicity.

With several Degraders advancing into clinical trials, the industry urgently needs interdisciplinary collaboration to drive technological innovation and standardization. In Return, TPD2026 Targeted Protein Degradation Forum will bring together academia and industry leaders to explore cutting-edge advancements, technical bottlenecks, and future directions in TPD, providing strategic insights and a collaborative platform to accelerate the development of next-generation protein degradation therapeutics.

Conference Major Sessions/Topics

• The Application and Development Strategy of Targeted Protein Degradation Technology
• Novel Targeted Protein Degradation Technologies and Drug Discovery 
• Cutting Edge Drug Design and Evaluation
• Discovery and Application of Novel Ligase Ligands
• Translational and Clinical Development
• CMC Development and Commercialization Strategies
• Development and Exploration of Next-Generation Targeted Protein Degraders

Currently we are receiving the podium/poster abstracts. If you are working in the above areas, you are invited to submit a proposal.

For more information, please contact:

David Xu
Program Manager
Organizing Committee
Email: david.xu@deliver-consulting.com
Phone: 86-137-7629-3901